Author:
Tran Nhi T.,Penny Tayla R.,Chan Kyra YY.,Tang Tanya,Papagianis Paris C.,Sepehrizadeh Tara,Nekkanti Lakshmi,Zahra Valerie A.,Pham Yen,Yawno Tamara,Nitsos Ilias,Kelly Sharmony B.,Thiel Alison M.,de Veer Michael,Alahmari Dhafer M.,Fahey Michael C.,Jenkin Graham,Miller Suzanne L.,Galinsky Robert,Polglase Graeme R.,McDonald Courtney A.
Abstract
Abstract
Background
Umbilical cord blood (UCB) cells are a promising treatment for preterm brain injury. Access to allogeneic sources of UCB cells offer the potential for early administration to optimise their therapeutic capacities. As preterm infants often require ventilatory support, which can contribute to preterm brain injury, we investigated the efficacy of early UCB cell administration following ventilation to reduce white matter inflammation and injury.
Methods
Preterm fetal sheep (0.85 gestation) were randomly allocated to no ventilation (SHAM; n = 5) or 15 min ex utero high tidal volume ventilation. One hour following ventilation, fetuses were randomly allocated to i.v. administration of saline (VENT; n = 7) or allogeneic term-derived UCB cells (24.5 ± 5.0 million cells/kg; VENT + UCB; n = 7). Twenty-four hours after ventilation, lambs were delivered for magnetic resonance imaging and post-mortem brain tissue collected. Arterial plasma was collected throughout the experiment for cytokine analyses. To further investigate the results from the in vivo study, mononuclear cells (MNCs) isolated from human UCB were subjected to in vitro cytokine-spiked culture medium (TNFα and/or IFNγ; 10 ng/mL; n = 3/group) for 16 h then supernatant and cells collected for protein and mRNA assessments respectively.
Results
In VENT + UCB lambs, systemic IFNγ levels increased and by 24 h, there was white matter neuroglial activation, vascular damage, reduced oligodendrocytes, and increased average, radial and mean diffusivity compared to VENT and SHAM. No evidence of white matter inflammation or injury was present in VENT lambs, except for mRNA downregulation of OCLN and CLDN1 compared to SHAM. In vitro, MNCs subjected to TNFα and/or IFNγ displayed both pro- and anti-inflammatory characteristics indicated by changes in cytokine (IL-18 & IL-10) and growth factor (BDNF & VEGF) gene and protein expression compared to controls.
Conclusions
UCB cells administered early after brief high tidal volume ventilation in preterm fetal sheep causes white matter injury, and the mechanisms underlying these changes are likely dysregulated responses of the UCB cells to the degree of injury/inflammation already present. If immunomodulatory therapies such as UCB cells are to become a therapeutic strategy for preterm brain injury, especially after ventilation, our study suggests that the inflammatory state of the preterm infant should be considered when timing UCB cells administration.
Funder
National Health and Medical Research Council Senior Research Fellowship
Inner Wheel Australia
Victorian Government’s Operational Infrastructure Support Program
Cerebral Palsy Alliance Australia Early Career Fellowship
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. McDonald CA, Castillo-Melendez M, Penny TR, Jenkin G, Miller SL. Umbilical cord blood cells for Perinatal Brain Injury: the right cells at the right time? Umbilical cord blood banking for clinical application. and Regenerative Medicine: IntechOpen; 2017.
2. Gupta AO, Wagner JE. Umbilical cord blood transplants: current status and evolving therapies. Front Pead. 2020;8.
3. Castillo-Melendez M, Yawno T, Jenkin G, Miller SL. Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front NeuroSci. 2013;7:194.
4. Zhou L, McDonald C, Yawno T, Jenkin G, Miller S, Malhotra A. Umbilical cord blood and cord tissue-derived cell therapies for neonatal morbidities: current Status and Future challenges. Stem Cells Transl Med. 2022;11(2):135–45.
5. Kotowski M, Litwinska Z, Klos P, Pius-Sadowska E, Zagrodnik-Ulan E, Ustianowski P, et al. Autologous cord blood transfusion in preterm infants - could its humoral effect be the kez to control prematurity-related complications? A preliminary study. J Physiol Pharmacol. 2017;68(6):921–7.